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ABSTRACT
The  decline  in  infectious  diseases  and  a  rise  in  chronic  diseases,  particularly 
cardiovascular disease (CVD), underlies the health trajectory of the 20th century. 
While much was known about CVD, particularly myocardial infarction and stroke, 
population data were problematic. Importantly, the peak and decline of the CVD 
epidemic in the 1960s and 1970s in some countries was not well recognized, leading 
to calls for more population-based disease surveillance. The WHO Multinational 
MONItoring of Trends and Determinants in CArdiovascular Disease (MONICA) 
Project  was  the  most  comprehensive  approach  to  better  understanding  disease 
etiology, incidence and trends at the population level. For a period of ten years or 
more in each center, from the early 1980s to the mid 1990s, MONICA implemented 
CVD surveillance in 21 countries. It included mortality, morbidity, coronary care, 
and population-based risk factor surveillance. The study is characterized by well-
described  methods  and  high  quality  data.  The  findings  show  large  differences 
between  different  centers  in  21  countries  and  provide  information  for  disease 
treatment and prevention. Many MONICA centers continued to actively collect 
data on populations within their countries. This experience provides a comprehensive 
approach for CVD patterns in the developed countries and the oncoming epidemic 
in the developing world.
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INTRODUCTION
The health trajectory of the 20th century is characterized by a decline in 
infectious diseases and a rise in life expectancy. Longer lives, coupled with 
increasing age-related incidence, resulted in increases in chronic diseases, 
particularly cardiovascular diseases (CVDs), becoming the leading causes 
of morbidity and mortality among adults in the industrialized world. That 
epidemiologic transition to chronic diseases is now occurring in developing 
countries. While clinicians were well aware of common diseases in their 
practice, epidemiologists were slow to note the rise and subsequent fall of 
CVD. This was first noted in a systematic way in the United States at the 
Bethesda Conference in 1978.1 In that year, it was already apparent that the 
CVD epidemic had peaked in the US in the 1960s when age-adjusted 
mortality began to fall. 
The origins of the CVD epidemic was studied for many years in the 
groundbreaking Framingham and Seven Countries studies.2,3 In addition to 
developing methods for surveillance of selected populations, these early 
studies demonstrated the importance of risk factors in the etiology of the 
major CVDs. However, the highly selected populations in these studies did 
not  lead  to  a  necessary  understanding  of  population  disease  patterns 
elsewhere.
The 1978 Bethesda conference emphasized the need to develop sur-
veillance  systems  to  better  understand  disease  trends  in  specific  and 
national populations.1 In the US, a number of programs were initiated, 
some strictly surveillance4,5 and some associated with population-based 
prevention  studies.6-8  Each  of  these  studies  contained  population-based 
surveys, hospital morbidity registration and mortality data.
Also stimulated by the Bethesda Conference, a similar and much larger 
effort began through the World Health Organization (WHO) Headquarters 
in Geneva, Switzerland, to bring together those interested in a multinational 
collaborative study. Multinational MONItoring of Trends and Determinants 
in CArdiovascular Disease, known as the WHO MONICA Project, aimed 
to study trends in coronary heart disease events, coronary care, stroke, and 
risk factors in multiple defined geographical populations, contemporaneously 
across the world.9 MONICA began in 1979 and enrolled investigators from 
26 countries, of which 21 completed the full study. MONICA took place 
mainly in Europe, but included centers in the US, Canada, China and 
Australasia. The task was enormous - collection of ten years of standardized 
data in areas of varying resources and disease patterns. That MONICA 
succeeded  in  collecting  quality  data  is  a  tribute  to  the  sponsors  and 
investigators. The methods are still used and applicable today and many of 
the centers continue this work, confirming MONICA’s importance.WHOMONICAProject:WhatHaveWeLearned? 375
While CVDs are declining in many industrialized nations, they continue 
to be leading causes of morbidity and mortality. In addition, the widespread 
application  of  sophisticated  technologies,  from  new  drugs  to  heart 
transplants, has led to increasing healthcare resources devoted to these 
diseases. These and other factors reinforce the need for quality surveillance, 
such as that initiated by MONICA. A recent report from the US Institute of 
Medicine reinforces the need for CVD surveillance.10 The following is a 
brief overview of MONICA, reviewing the strategies and outcomes from 
this unique surveillance project.
BACKGROUND
Fig. 1. Causes of the Decrease in Cardiovascular Mortality. Can we identify factors 
causing the coronary mortality rate decrease and measure their contribution? BP = 
blood pressure; CCU = cardiopulmonary resuscitation; EMS = emergency medical 
service.
Source: Reprinted from American Journal of Cardiology, vol. 54, Levy RI, Causes of the 
decrease in cardiovascular mortality, pages 7C-13C, 1984, with permission from Elsevier.64
The observation of an emerging epidemic and subsequent declining pattern 
raised many questions. Where were the trends going? How did they affect 
different populations? What were the causes (Figure 1)? A number of cohort 
studies had been undertaken in the 1950s and 1960s including the Framingham 
Study, the Tecumseh Michigan Study and the Puerto Rican Heart Study.2,11,12 
These projects were aimed at determining the causes of CVD focusing on 
healthy people and followed them forward for disease events, they did not 
study population trends. Only Framingham continues today.2 In the same era 376 PublicHealthReviews,Vol.33,No2
of the 1950s, the Seven Countries Study set a standard for multi-center cohort 
studies.3 It was based on the belief that significant differences in disease 
patterns would be observed between populations that may not be apparent 
within  populations,  revealing  underlying  mechanisms.  This  study  also 
continues today. In 1969, the WHO Regional Office for Europe initiated a 
series of community myocardial infarction registers to record population 
incidence  (including  coronary  deaths)  and  outcomes.  However,  these 
registers  were  not  generally  maintained  beyond  two  or  three  years.13 
Subsequent to the Bethesda Conference in 1988, there were new observations 
by Uemura and Pisa showing international trends in cardiovascular mortality 
in the period following the Second World War confirming large differences 
between countries.14 CVD patterns were definitely changing. Why?
Ten years after the 1978 first Bethesda conference, a second international 
conference was convened by the National Heart, Lung and Blood Institute 
(NHLBI) in Bethesda in August 1988 to review progress.15 The establishment 
of  several  studies  in  the  US4,5  and  the  enhanced  capability  of  the  US 
National Health and Nutrition Examination Survey (NHANES)16 began to 
provide data. These population studies link morbidity and mortality from 
CVDs with population measurements of risk factors and health behaviors. 
Community-based Heart Health Programs also added to the information 
about population trends.17 
Table 1
MONICAMeasuresandHypotheses
MONICA Measurements
A. Incidence rates (fatal [=mortality] and nonfatal events) over ten years
B. Case fatality (percentage fatal at 28 days from onset) over ten years
C. Risk factor levels and trends through repeated population surveys (2 or 3)
D. Medical care on two occasions during surveillance, continuous in some centers
Potential Associations of Trends in These Measurements
A. Risk factors and incidence (subject of first null hypothesis on trends)
B. Medical care and case fatality (subject of second null hypothesis on trends)
C. Incidence and case fatality (explored cross-sectionally)
D. Medical care and incidence (incorporated in analyses for second null hypothesis)
E. Risk factors and case fatality (not analyzed so far but now historical data)
F. Medical care and risk factors (not analyzed so far but now historical data)WHOMONICAProject:WhatHaveWeLearned? 377
By this time, MONICA collaborators and the US Atherosclerosis Risk 
in Communities (ARIC) study participants, who had worked together at 
first,  were  implementing  somewhat  different  protocols.9,18  Beyond  sur-
veillance of disease in defined populations, MONICA employed repeated 
independent random sample population surveys incorporating a few core 
risk factors. Meanwhile, ARIC studied a large cohort with many different 
risk factors measured along with community-based disease surveillance.
MONICA was a comprehensive study examining numerous questions 
in  the  international  setting  with  well-controlled,  standardized  methods. 
MONICA included core measurements with the goal of testing several 
hypotheses, primarily on coronary heart disease (Table 1), but also for 
stroke at some of the study centers. In addition to studies on the core disease 
patterns and risk factors, there were numerous optional sub-studies initiated 
by  MONICA  investigators  and  follow-up  studies  on  their  survey 
participants. The collaborative MONICA optional studies are shown in 
Table 2 and there were also many additional locally based optional studies 
reported by individual centers.9
Table 2
MONICAOptionalStudies
A. Study on nutrition
B. Study on anti-oxidant vitamins and polyunsaturated fatty acids
C. Psychosocial study
D. Study of physical activity
E. Study of drugs
F. Study on hemostatic risk factors
STUDY STRUCTURE
The MONICA study began in 1979 with organizational meetings at the 
WHO. Initially, funding for coordination and international travel came from 
the WHO: individual centers were funded locally from local and central 
governments, charitable foundations and others. The establishment of the 
Data Centre in Helsinki at the National Public Health Institute in Finland led 
to increasing Finnish commitment. The US NHLBI funded quality control 
work through WHO. Additional funding was obtained from the European 
Commission and a system was established to accept industry grants. 378 PublicHealthReviews,Vol.33,No2
The study was led by a council of principal investigators meeting as a 
group nine times during the 23 years of the study (Table 3). They served in 
the  manner  of  a  parliament  with  oversight  for  decision-making.  A 
subcommittee, the MONICA Steering Committee, managed the project, 
having 29 meetings over the years, 116 telephone conferences, and a torrent 
of  e-mail  communications  as  early  as  1988.  The  steering  committee 
contained both elected and ex-officio members. The elected members were 
selected from the principal investigators at the collaborating sites. The 
WHO  provided  the  MONICA  Management  Centre,  hosting  the  early 
meetings.
Table 3
MONICACenters–PrincipalandCo-PrincipalInvestigators
DuringDataCollection.
MONICA Centers Principal and Co-Principal Investigators
Australia-Newcastle (AUS-NEW, AN)  Stephen Leeder, Annette Dobson
Australia-Perth (AUS-PER, AP)  Michael Hobbs, Konrad Jamrozik
Belgium-Ghent/Charleroi (BEL-GCH, BE) Guy De Backer, Marcel Kornitzer
Canada-Halifax (CAN-HAL, CA)
Hermann Wolf, Ronald Gregor, Iqbal Bata, 
Ross Mackenzie
China-Beijing (CHN-BEI, CN)
Zhaosu Wu, Yingkai Wu, Chonghua Yao, Dong 
Zhao
Czech Republic (CZE-CZE, CZ) Zdenka Škodová
Denmark-Glostrup (DEN-GLO, DN) Marianne Schroll
Finland (FIN-FIN, FI) Jaakko Tuomilehto, Pekka Puska
France-Country Coordinating Centre Pierre Ducimetière, JL Richard
France-Lille (FRA-LIL, FL)
Philippe Amouyel, Michele Montaye, JL 
Salomez, MC Nuttens, G Luc
France-Strasbourg (FRA-STR, FS) Dominique Arveiler, Paul Schaffer
France-Toulouse (FRA-TOU, FT)
Jean Ferrières, Jean-Bernard Ruidavets, Jean-
Pierre Cambou
Germany-Augsburg (GER-AUG, GA) Ulrich Keil
Germany-Bremen (GER-BRE, GB)
Eberhard Greiser, Katrin Janhsen, Bertram 
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Table 3 Contd.
MONICA Centers Principal and Co-Principal Investigators
Germany-East Germany (GER-EGE, GE) Lothar Heinemann, Wolfgang Barth
Iceland (ICE-ICE, IC)
Nikulás Sigfússon, Inga Ingibjörg 
Guömundsdóttir
Italy-Country Coordinating Centre Simona Giampaoli, Alessandro Menotti
Italy-Brianza (ITA-BRI, IT) Marco Ferrario, Giancarlo Cesana
Italy-Friuli (ITA-FRI, IF)
Diego Vanuzzo, Giorgio Antonio Feruglio, 
Lorenza Pilotto
Lithuania-Kaunas (LTU-KAU, LT)
Juozas Bluzhas, Stase Domarkiene, Daiva 
Rastenyte
New Zealand-Auckland (NEZ-AUC, NZ) Robert Beaglehole, Rod Jackson
Poland-Tarnobrzeg Voivodship (POL-TAR, 
PT)
Andrzej Pajak, Jan Sznajd
Poland-Warsaw (POL-WAR, PW) Stefan Rywik, Grazyna Broda
Russia-Moscow (RUS-MOS, RM)
George Zhukovsky, Sergei Fedotov, Tatyana 
Varlamova
Russia-Novosibirsk (RUS-NOV, RN)  Yuri Nikitin
Spain-Catalonia (SPA-CAT, SP) Susana Sans, Ignacio Balaguer-Vintró
Sweden-Gothenburg (SWE-GOT, SG)  Lars Wilhelmsen, Annika Rosengren
Sweden-Northern Sweden (SWE-NSW, 
SN)
Kjell Asplund, Torbjorn Messner, Per-Olov 
Wester, Fritz Huhtasaari
Switzerland (SWI-SWI, SW)
Felix Gutzwiller, Gianfranco Domenighetti, 
Fred Paccaud
United Kingdom-Belfast (UNK-BEL, UB) Alun Evans
United Kingdom-Glasgow (UNK-GLA, 
UG)
Hugh Tunstall-Pedoe, Caroline Morrison, 
Cairns Smith, Graham Watt
United States-Stanford (USA-STA, US) Stephen Fortmann
Yugoslavia-Novi Sad (YUG-NOS, YU) Milutin Planojevic, Djordje Jakovljevic.380 PublicHealthReviews,Vol.33,No2
In  addition  to  the  administrative  structures,  a  number  of  important 
functional  centers  were  established.  The  Helsinki  Data  Centre  was 
responsible  for  data  quality  and  management,  analysis  and  archives. 
Laboratory  quality  control  for  lipids,  including  total  cholesterol,  HDL 
cholesterol  and  thiocyanate  (a  measure  of  cigarette  smoking),  was 
established in Prague in the Czech Republic. This centre worked in close 
collaboration with the Lipid Standardization Program at the Centers for 
Disease Control and Prevention, Atlanta, Georgia. An electrocardiogram 
(ECG) coding center was established in Budapest, Hungary to implement 
the Minnesota Code.19 Quality control of event registration was centered in 
Scotland  at  the  University  of  Dundee  which  was  responsible  for  the 
diagnostic algorithms for classifying myocardial infarction and coronary 
deaths, and for distributing test case histories for coding. Finally, health 
services data, with standardized measures of medical and surgical care for 
CVD, was overseen by the University of Western Australia.9,20
The  collection  of  high  quality  data  from  multiple  centers  on  four 
continents  with  different  languages  and  healthcare  systems  presented 
unique challenges. The methods utilized, including MONICA diagnostic 
criteria and classifications are detailed in the MONICA Manual.18 The 
dedication to quality began with the development of standardized data 
collection methods followed by training sessions for those collecting the 
data. Quality control was ongoing and overall quality was evaluated again 
after the study was finished to test the robustness of the results of data 
analyses.
POPULATION
Originally  each  center  was  expected  to  have  a  population  adequate  to 
generate  200  coronary  deaths  annually  in  men  below  age  65.  Study 
populations,  defined  by  geographic  boundaries  and  healthcare  delivery 
patterns, ranged from 100,000 to 1 million population. In all, a population 
of  10  million  was  included  in  the  study.  The  mortality  and  hospital 
surveillance were continuous, while the population surveys were the result 
of independent probability sampling at two to three distinct times over the 
ten years. There was also an obligatory two periods of recording medical 
coronary care during the years of surveillance of coronary events.WHOMONICAProject:WhatHaveWeLearned? 381
DATA COLLECTION AND METHODS 
Mortality was collected from usual sources in each of the communities. 
However, there were differences in reporting methods which may have 
resulted  in  some  variability.21-23 All  CVD  deaths,  plus  ancillary  causes 
which might be CVD, were collected. In addition, other major chronic 
disease categories including cancer, lung disease and ill-defined conditions 
were  collected  as  well  as  all-causes  mortality.  Mortality  trends  were 
followed over the ten years of the study at each center, both for “official 
trends”  from  the  local  death  register,  not  validated;  and  for  trends  in 
validated events subject to MONICA scrutiny and reclassification.
DEMOGRAPHIC DATA
For  each  designated  geographic  population  administrative  data  were 
sought.  This  was  either  based  on  decennial  census  data  with  yearly 
adjustments  or  from  continuously  updated  population  registers,  as 
practiced, for example, in Scandinavian countries. Resulting numbers were 
subjected to quality assessment in Helsinki.9
CORONARY EVENT REGISTRATION
Coronary event registration for living cases was focused on hospitals. In 
different countries, different healthcare systems, regulations and privacy 
concerns were considered. In addition, all potential cases that did not come 
to hospital before death, and died out-of-hospital from possible coronary 
heart  disease,  were  scrutinized  and  classified  using  MONICA  criteria. 
MONICA  criteria  were  used  to  classify  death,  particularly  that  from 
coronary heart disease.18,21,22 All MONICA centers extracted a basic dataset 
with a common protocol.
A variety of data were collected using cold pursuit or hot pursuit. 9,18,21 
These  included  demographic  information,  medical  and  diagnostic  data 
including symptoms, enzymes, electrocardiograms and autopsy findings 
when performed.21 MONICA diagnostic criteria for myocardial infarction 
and coronary deaths9,18,21 were widely used in the 1980s and 1990s, although 
they have recently been superseded.24382 PublicHealthReviews,Vol.33,No2
CORONARY CARE
Some  centers  recorded  hospital  coronary  care  continuously,  but  it  was 
obligatory to measure it for two periods during the decade of surveillance. 
Among many other items, a template for treatment data was included. It 
involved eight medications and treatments, such as thrombolysis or invasive 
reperfusion (e.g., angioplasty or coronary artery bypass grafts) including 
those used before the onset of the attack, during hospitalization, and at 
discharge from hospital. These data highlighted large differences between 
centers. 25
POPULATION SURVEYS
Free-living populations aged 25- or 35-64 were collected in each MONICA 
collaborating center. Twelve hundred to 1,600 individuals were required 
for an adequate sample size. In reality, 1,000-3,000 citizens were selected 
by independent sampling two or three times over the ten years of the study. 
Sampling was a single stage or multi-stage procedure. Participation was 
excellent in most centers with a median of 70-79% participation, trending 
downward in many populations over the study decade.
Data collection in the population included major indicators of CVD and 
demographic information. Smoking was ascertained by interview or self-
administered  questionnaire  and  validated  by  chemical  measurements. 
Blood pressure was measured manually by a standard sphygmomanometer 
or a random zero sphygmomanometer26 in all the centers. Training of staff, 
selection of devices and the use of appropriate cuffs were essential to this 
measure. Blood was collected for total cholesterol and HDL cholesterol. 
Staff were trained in the appropriate collection and processing methods. 
Height, weight and waist circumference were measured using standard 
protocols.
Risk factors were combined in a risk factor score used in the analyses.
DATA CONTROL
The data were shipped to the MONICA Data Centre in Helsinki. As the 
study  progressed,  transmission  of  event  and  survey  data  moved  from 
magnetic tape to floppy disks and finally e-mail, while annual reporting of 
demographic data and official mortality data began on paper forms. The 
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for corrections to the field centers. Data were only changed if the field 
center agreed. This was partly due to the importance of the source and a 
policy to allow local control of data from that center for individual analyses. 
Matching the data in the Data Centre with that of the local center removed 
disparities in the analytic phase.
Individual  reference  centers  were  established  for  the  collaborative 
optional  studies  including:  the  nutrition  measures;  vitamins  and  poly-
unsaturated fatty acid; physical activity; psychosocial factors; drug use 
prehospital; and hemostatic factors. Data for ancillary studies was analyzed 
at the reference centers.
MONICA RESULTS
The MONICA experience resulted in three major publications27-29 in the 
peer-reviewed literature. Collaborative publications can be accessed at the 
MONICA website,30 but there are many more produced by single centers 
based on their local findings and optional studies. Selected below are some 
of the major findings involving mortality, coronary events and risk factor 
changes in 21 countries with 38 populations. It provides a dramatic picture 
of international differences in CVDs. It is comprehensive in scope and 
detailed in information. The MONICA database is potentially available for 
other collaborative analyses, although now becoming a dated resource. 
There  are  several  considerations  to  remember  when  analyzing  the 
MONICA data. First is the age range, appropriate when the study was 
designed, of 25- or 35-64 years, when the concern was premature CVD. 
This age range remains a concern, but much of the disease is now in the 
older population. Second is the recognition that there are different years for 
surveillance in the study. Although most of the centers did three surveys 
over a ten-year period, the calendar years were not identical as different 
centers entered the study at different times. Therefore, the comparisons 
detailed below are not always for identical years. Most centers continued to 
collaborate  through  years  of  major  international  upheaval,  including 
political change in Eastern Europe, and other changes of government, often 
having to refresh and replace their initial source of funding.
In  addition  to  providing  international  information  on  incidence, 
prevalence  and  trends,  MONICA  also  contributed  substantially  to  the 
methodology  of  population  surveillance.  This  included  statistical 
methods,31,32 measurement issues,31-33 epidemiologic methods,34-38 quality 
assurance,39,40 and diagnostic criteria.18,21384 PublicHealthReviews,Vol.33,No2
MORTALITY
The mortality data from MONICA were extracted from official statistics 
from each center. The age window for mortality was 35-64 years. Shown in 
Figure  2  is  a  comparison  of  all-cause  mortality  across  the  MONICA 
centers. It includes coronary heart disease, stroke, other CVD and non-
CVD. All of the populations are age-adjusted to the 1970s world standard 
population.41 Cardiovascular mortality varied greatly between MONICA 
sites. There are three to five fold differences between the most affected and 
those  that  have  the  lowest  rates.  Coronary  heart  disease,  while  the 
commonest single cause of death, contributed a modest fraction of mortality 
in the 35-64 age group. In all populations, men had significantly higher all-
cause  mortality  rates  than  women,  and  substantially  higher  rates  for 
coronary heart disease. 
Fig. 2. Death rates (ages 35-64) from various causes: final three years of coronary-
event registration.
Source: MONICA Monograph and Multimedia Sourcebook, 2003.9WHOMONICAProject:WhatHaveWeLearned? 385
CORONARY EVENT RATES
MONICA used hospital and mortality registration data from each center for 
the numerator in event rates.42 Demographic data for the denominator was 
gathered  from  census.  All  data  were  adjusted  to  the  world  standard 
population.41 These data are illustrated for the final three years of the study 
in  Figure  3.  Again,  there  are  enormous  differences  between  different 
populations. In men, Glasgow in the United Kingdom and North Karelia in 
Finland have eight to ten times the coronary event rate of Beijing in China. 
Similarly, among women, Glasgow has roughly ten times the rate of Beijing 
and Toulouse in France.
Fig. 3. Coronary-event rates (ages 35-64): final three years of registration.
Source: MONICA Monograph and Multimedia Sourcebook, 2003.9
MONICA was primarily a study of trends over time, specifically ten 
years. In Figure 4, the average annual changes in coronary event rates are 
depicted. The 95 percent confidence intervals determine the width of the 
bars. Most populations were tending to an annual decline in event rates, 
with Finland reporting the largest reduction over time for men. Despite this 
overall trend, eight of the 38 populations recorded increasing event rates in 
men. Among women there were also predominantly decreasing event rates 
with Moscow, Russia and Strasbourg, France having the largest declines 
but, here again, 12 of the 38 populations saw an increase.386 PublicHealthReviews,Vol.33,No2
Fig. 4. Average annual change in coronary-event rates.
Source: MONICA Monograph and Multimedia Sourcebook, 2003.9
RISK FACTOR SURVEILLANCE
Each MONICA center identified free-living individuals aged 25- or 35-64 
and measured their health status, specifically assessing risk factors for 
CVD. The major risk factors considered were cigarette smoking, blood 
pressure, blood cholesterol and body mass index. However, there were 
other factors considered besides these classical risk factors, both in the 
entire population and in substudies. The risk factor data are substantial and 
this review will only touch on two variables: cigarette usage and a risk 
factor score.
Cigarette  usage  among  men  varied  greatly  between  the  MONICA 
centers from a very high rate of use in Beijing to very low rates in Australia, 
New Zealand and Sweden (Figure 5). Many other countries, particularly 
those in Eastern Europe, also had very high rates of tobacco use. Among 
women, smoking rates in all populations were generally lower than in men, 
the  exceptions  being  those  with  the  highest  smoking  rates,  Glostrup, 
Denmark and Glasgow, UK, where the rates in men and women were the 
same. Low rates were reported among women in Lithuania and Russia. WHOMONICAProject:WhatHaveWeLearned? 387
Fig. 5. Prevalence of daily cigarette smokers (ages 25-64) in the final risk-factor 
survey.
Source: MONICA Monograph and Multimedia Sourcebook, 2003.9
Fig. 6. Ten-year change in prevalence of daily cigarette smokers.
Source: MONICA Monograph and Multimedia Sourcebook, 2003.9388 PublicHealthReviews,Vol.33,No2
Trends in daily smoking are quite striking. Most populations experienced 
declines in the ten-year prevalence of daily cigarette smoking (Figure 6). 
However, Beijing experienced a substantial increase in the number of men 
who were daily cigarette smokers, as did several other locations. Among 
women, cigarette smoking increased in the majority of populations.9
The  coronary  risk  factor  score  was  developed  for  MONICA  to 
summarize the risk factor data collected on individuals. It was derived from 
Scandinavian cohort studies and emphasized predictors of mortality. The 
risk  score  included  cigarette  smoking,  systolic  blood  pressure,  total 
cholesterol and body mass index. The first three were major contributors to 
the score but weight, as summarized by body mass index, contributed only 
modestly. The mean risk score was 6-7.5 in men and 5.7-6.5 in women. As 
seen in Figure 7, risk scores declined substantially in most populations for 
both men and women. However, men in Beijing, Yugoslavia and Switzerland 
demonstrated substantial increases in the coronary risk factor score. Among 
women,  populations  in  Switzerland,  Canada  and Yugoslavia  also  saw 
significant increases in the risk factor score. The observation that most of 
the countries saw significant reductions in the risk factor score is important 
as it is should predict later event rates, although some had a deterioration in 
scores.9
Fig. 7. Ten-year change in average coronary risk-factor score.
Source: MONICA Monograph and Multimedia Sourcebook, 2003.9WHOMONICAProject:WhatHaveWeLearned? 389
BEYOND THE MONICA CORE
The combined results as of 2002 present only part of the picture.9 MONICA 
trained  a  cadre  of  cardiovascular  epidemiologists  in  21  countries  in 
hypothesis-driven studies, based on a population perspective, collecting 
data according to agreed definitions, with transparent quality assurance 
procedures and results. Many MONICA centers continue collaboration 
through the Helsinki Data Centre, (now a European reference center for 
population health surveys) in the MOnica Risk, Genetics, Archiving and 
Monograph  (MORGAM)  Project,  coordinated  from  Belfast.43  This  has 
collected data from MONICA and other survey populations with archived 
material and follow-up to study other components of risk through genetic 
material and biomarkers. 
The MONICA dataset is rather underexploited, but one late novel analysis 
pooled the changes in blood pressure (by contrast most MONICA analyses 
were based on scatter plots). This showed that the average decline in blood 
pressure  in  MONICA  populations  between  their  first  and  final  surveys 
occurred at all levels, being the same for the 20th, 50th and 80th centiles and the 
mean. This suggested that the decline was from overall mass population 
change, rather than from increasing medication of those in the population 
diagnosed as hypertensive (in the upper centiles) and on treatment.44
While  the  study  was  ongoing,  many  centers  presented  their  local 
information  in  published  manuscripts.  Following  the  end  of  MONICA 
many of the centers, with their own funding, continued to use the established 
methods for a number of different studies. These included extension of the 
follow-up of the cohorts, new population survey groups and expansion of 
the age window. MONICA was also compared to other ongoing cohort 
studies and the data were used to evaluate other diseases.
The ancillary studies have been particularly productive. For example, 
the study of stroke, which involved 15 centers, has published regularly on 
their findings.45,46 Studies of thrombotic and inflammatory markers have 
been presented.47 Environmental factors, such as temperature and baro-
metric pressure and their effects on CVD, have been published by the 
French group along with the association of diet with smoking.48,49 The use 
of complementary medications in Northern Sweden has been the subject of 
an analysis.50 With the wealth of information and stored data, including 
blood samples, work will continue on the original MONICA datasets.
Many centers have extended various elements of the MONICA protocol 
up through the current period with governmental and/or foundation support. 
These  centers  have  continued  to  register  and  follow-up  myocardial 
infarction rates in their survey areas.51-54 Others continued the surveillance 390 PublicHealthReviews,Vol.33,No2
and expanded their age window, usually to age 74, to more closely track the 
migration  of  CVD  to  older  ages.51,54,55  Some  centers  have  performed 
additional population surveys using the same sampling frame. These have 
included the groups in northern Sweden and France.56,57 Some MONICA 
centers have combined to look at specific areas, such as alcohol,58 or with 
other cohorts, such as the Münster Heart Study (PROCAM) evaluating 
lipids,59 and finally some centers have begun to look at other diseases in the 
cohort, such as diabetes.60,61
Many of the centers were unable to continue the costly and high level of 
surveillance originally performed by MONICA and now complicated by a 
change to ICD10 classifications, the advent of new biomarkers for diagnosis 
of myocardial infarction, and changes in the clinical terminology of acute 
coronary events.24 However, there are outcomes and experience lasting 
beyond  the  original  study.  MONICA  has  provided  the  standards  and 
platform for population-based disease surveillance of mortality, morbidity 
and population risk.
FUTURE OF SURVEILLANCE IN 2011
The Institute of Medicine in the US unveiled a framework for surveillance of 
cardiovascular and chronic lung diseases at the instigation of the NHLBI and 
the CDC. Their charge was to develop a framework for building a national 
chronic disease surveillance system focused primarily on cardiovascular and 
pulmonary diseases that is capable of providing data for analysis of race, 
ethnic, socioeconomic and geographic region disparities in incidence and 
prevalence, functional outcomes, measured risk factors and clinical care 
delivery. The committee recognized that current surveillance data was not 
standardized, could not be linked across sources and was often not accessible. 
They also recognized that the advent of widespread use of electronic health 
records (EHR) had great potential for collecting and analyzing these data but 
that there were serious barriers with different systems and technologies. The 
recommendations were for the establishment of systems to address the needs 
for  actionable  indicators  of  cardiovascular  and  pulmonary  health  in  the 
population across the nation and within vulnerable subgroups.10 
There  are  also  ongoing  efforts  in  Europe  to  continue  population 
surveillance. The  European  Society  of  Cardiology  (ESC)  established  a 
number of ongoing registries over the past decade under the title Euro 
Heart Survey.62 These include clinical data collection in multiple countries 
according to a standardized format with coordination at the European Heart 
House in Nice, France. There are surveys on: Acute Coronary Syndromes, WHOMONICAProject:WhatHaveWeLearned? 391
Adult Congenital Heart Disease, Angina Pectoris, Arrhythmias, Coronary 
Interventions, Diabetes, Heart Failure, Preventive Practice (Eurospire) and 
Valvular Heart Disease.
There  are  also  ongoing  efforts  to  establish  a  European  Health 
Examination Survey. From 2003-2008, the European Union funded a study 
of  the  Feasibility  of  a  European  Health  Examination  Survey  (FEHES) 
through  the  Programme  of  Community Action  in  Public  Health.63 This 
initial effort, led by MONICA investigators from the coordinating center in 
Finland, is currently in a pilot phase (2009-2011).64
The spirit and accomplishments of MONICA continue to contribute.
Acronyms list:
CVD = Cardiovascular disease
MONICA = The WHO Multinational MONItoring of Trends and Determinants in 
CArdiovascular Disease Project
NHLBI = The National Heart, Lung and Blood Institute
Acknowledgements: Much of the material and all the graphics except Figure 1 are 
taken, with permission, from the MONICA Monograph and Multimedia Sourcebook 
published in 2003 and available from the World Health Organization, but also on 
the internet at: http://www.ktl.fi/monica/public/monograph.html. The author thanks 
Professor Hugh Tunstall-Pedoe for his comments and editorial assistance.
REFERENCES
1.  Havlik RJ, Feinleib M, editors. Proceedings of the Conference on the Decline 
in Coronary Heart Disease Mortality, October 24-25, 1978. Washington, DC: 
National  Heart,  Lung  and  Blood  Institute,  1979,  NIH  publication  No. 
79-1610, DHES.
2.  Dawber TR. The Framingham Study: The Epidemiology of Atherosclerotic 
Disease. Cambridge, MA: Harvard University Press; 1980.
3.  Keys A. Seven Countries: A Multivariate Analysis of Death and Coronary Heart 
Disease. Cambridge, MA and London, England: Harvard University Press; 
1980.
4.  Brown SA, Hutchinson R, Morrisett J, Boerwinkle E, Davis CE, Gotto AM Jr, 
et al. Plasma-lipid, lipoprotein cholesterol, and apoprotein distributions in 
selected United States communities: the Atherosclerosis Risk in Communities 
(ARIC) Study. Arteriosclerosis and Thrombosis. 1993;13:1139-58.
5.  Gillum RF, Hannan PJ, Prineas RJ, Jacobs DRE Jr, Gomez-Marin O, Luepker 
RV, et al. Coronary heart disease mortality trends in Minnesota, 1960-1980: 
the Minnesota Heart Survey. Am J Public Health. 1984;74:360-2.
6.  Luepker RV, Murray DM, Jacobs DR, Mittelmark MB, Bracht N, Carlaw R, et 
al. Community education for CVD prevention: risk factor changes in the 
Minnesota Heart Health Program. Am J Pub Health. 1994;84:1383-93.392 PublicHealthReviews,Vol.33,No2
7. Winkleby MA, Taylor CB, Jatulis D, Fortmann SP. The long-term effects of a 
cardiovascular disease prevention trial: the Stanford Five-City Project. Am J 
Pub Health. 1996;86:1773-9.
8. Carleton RA, Lasater TM, Assaf AR, Feldman HA, McKinlay S. The Pawtucket 
Heart Health Program: community changes in cardiovascular risk factors and 
projected disease risk. Am J Pub Health. 1995;85:777-85.
9. Tunstall-Pedoe  H  (editor),  for  the  WHO  MONICA  Project.  MONICA 
Monograph  and  Multimedia  Sourcebook.  World  Health  Organization, 
Geneva, 2003.
10. Institute  of  Medicine.  A  Nationwide  Framework  for  Surveillance  of 
Cardiovascular  and  Chronic  Lung  Diseases.  IOM. Washington,  DC: The 
National Academies Press; 2011.
11. Butler  WJ,  Ostrander  LD  Jr,  Carman  WJ,  Lamphiear  DE.  Mortality  from 
coronary heart disease in the Tecumseh Study: long-term effect of diabetes 
mellitus,  glucose  tolerance  and  other  risk  factors.  Am  J  Epidemiol. 
1985;121:541-7.
12. Costas R, Garciapalmieri MR, Nazario E, Sorlie PD. Relation of lipids, weight 
and physical activity to incidence of coronary heart disease: Puerto Rico 
Heart Study. Am J Cardiol. 1978;42:653-8.
13. World Health Organization Regional Office for Europe. Myocardial infarction 
community registers, Copenhagen, 1976 (Public Health in Europe 5).
14. Uemura K, Pisa Z. Trends in cardiovascular disease mortality in industrialized 
countries since 1950. World Health Stat Q 1988;41:156-78.
15. Higgins M, Luepker RV, editors. Trends and determinants of coronary heart 
disease mortality: international comparisons. Int J Epidemiol. 1989;18:S1-
235.
16. Madans JH, Cox CS, Kleinman JC, Makuc D, Feldman JJ, Finucane FF, et al. 
10 years after NHANES-1: mortality experience at initial follow-up, 1982-
84. Pub Health Reports. 1986;101:474-81.
17. Winkleby,  MA,  Feldman,  HA,  Murray,  DM.  Joint  analysis  of  three  U.S. 
community intervention trials for reduction of cardiovascular disease risk. J 
Clin Epidemiol. 1997;50:645-58.
18. WHO MONICA Project. MONICA Manual. (1998-1999). 31 March 1999. 
Available  from  URL:  http://www.ktl.fi/publications/monica/manual/index.
htm (Accessed 2 August, 2011).
19. Prineas  RJ,  Crow  RS,  Blackburn  HW.  The  Minnesota  Code  Manual  of 
Electrocardiographic Findings: Standards and Procedures for Measurement 
and Classification. J. Wright, 1982.
20. WHO MONICA Project. MONICA Quality assessment reports. MONICA Web 
Publications 2-18. 12 August, 2010. Available from URL: http://www.ktl.fi/
publications/monica/index.html (Accessed 2 August, 2011).WHOMONICAProject:WhatHaveWeLearned? 393
21. Tunstall-Pedoe  H,  Kuulasmaa  K, Amouyel  P, Arveiler  D,  Rajakangas AM, 
Pajak A, for the WHO MONICA Project. Myocardial infarction and coronary 
deaths  in  the World  Health  Organization  MONICA  Project.  Registration 
procedures, event rates, and case-fatality rates in 38 populations from 21 
countries in four continents. Circulation. 1994;90:583-612. 
22. Asplund K, Tuomilehto J, Stegmayr B, Wester PO, Tunstall-Pedoe H, for the 
WHO  MONICA  Project.  Diagnostic  criteria  and  quality  control  of  the 
registration of stroke events in the WHO MONICA project. Acta Med Scan 
Suppl 1988;728:26-39.
23. Thorvaldsen P, Asplund K, Kuulasmaa K, Rajakangas AM, Schroll M, for the 
WHO MONICA Project. Stroke incidence, case fatality, and mortality in the 
WHO MONICA Project. Stroke. 1995;26:361-7.
24. Tunstall-Pedoe  H.  Descriptions  and  definitions  of  myocardial  infarction  – 
personal reminiscences and a challenge. Int J Epidemiol. 2011;40:147-9.
25. Mähönen M, Cepaitis Z, Kuulasmaa K, for the WHO MONICA Project. Quality 
assessment  of  acute  coronary  care  data  in  the WHO  MONICA  Project. 
February 1999. Available from URL: http://www.ktl.fi/publications/monica/
accqa/accqa.htm, URN:NBN:fi-fe19991081 (Accessed 2 August, 2011).
26. DeGaudemaris  R,  Folsom AR,  Prineas  RJ,  Luepker  RV.  The  random-zero 
versus  the  standard  mercury  sphygmomanometer:  a  systematic  blood 
pressure difference. Am J Epidemiol. 1985;121:282-90.
27. Tunstall-Pedoe  H,  Kuulasmaa  K,  Mahonen  M,  Tolonen  H,  Ruokokoski  E, 
Amouyel P. Contribution of trends in survival and coronary-event rates to 
changes in coronary heart disease mortality: 10-year results from 37 WHO 
MONICA Project populations. Lancet 1999;353:1547-57.
28. Kuulasmaa K, Tunstall-Pedoe H, Dobson A, Fortmann S, Sans S, Tolonen H, 
Evans A, Ferrario M, Tuomilehto J. Estimation of contribution of changes in 
classic  risk  factors  to  trends  in  coronary-event  rates  across  the  WHO 
MONICA Project populations. Lancet 2000;355:675-87.
29. Tunstall-Pedoe H, Vanuzzo D, Hobbs M, Mahonen M, Capaitis Z, Kuulasmaa 
K,  Keil  U.  Estimation  of  contribution  of  changes  in  coronary  care  to 
improving survival, event rates, and coronary heart disease mortality across 
the WHO MONICA Project populations. Lancet 2000;355:688-700.
30. The WHO MONICA Website. 19 September, 2009. URL: http://www.ktl.fi/
monica/ (Accessed 2 August, 2011).
31. Chambless LE, Dobson AJ, Patterson CC, Raines B. On the use of a logistic 
risk score in predicting risk of coronary heart disease. Stat Med. 1990;9:385-
96.
32. Kulathinal SB, Kuulasmaa K, Gasbarra D. Estimation of an errors-in-variables 
regression model when the variances of the measurement errors vary between 
the observations. Stat Med. 2002;21:1089-101.394 PublicHealthReviews,Vol.33,No2
33. Kuulasmaa K, Dobson A, for the WHO MONICA Project. Statistical issues 
related to following populations rather than individuals over time. Bulletin of 
the International Statistical Institute: Proceedings of the 51st Session; 1997 
Aug  18-26;  Istanbul, Turkey. Voorburg:  International  Statistical  Institute; 
1997.  Book  1;  295-8.  Also  available  from  URL:  http://www.ktl.fi/
publications/  monica/isi97/isi97.htm (Accessed 15 December 2011).
34. Tolonen H, Dobson A, Kulathinal S, for the WHO MONICA Project. Effect on 
trend  estimates  of  the  difference  between  survey  respondents  and  non-
respondents: results from 27 populations in the WHO MONICA Project. Eur 
J Epidemiol. 2005;20:887-98.
35. Wolf HK, Kuulasmaa K, Tolonen H, Sans S, Molarius A, Eastwood BJ, for the 
WHO MONICA Project. Effect of sampling frames on response rates in the 
WHO MONICA risk factor surveys. Eur J Epidemiol. 2005;20:293-9.
36. Tolonen  H,  Ferrario  M,  Kuulasmaa  K,  for  the  WHO  MONICA  Project. 
Standardization of total cholesterol measurement in population surveys -   
pre-analytic  sources  of  variation  and  their  effect  on  the  prevalence  of 
hypercholesterolaemia. Eur J Cardiovasc Prev Rehabil. 2005;12:257-67.
37. Barnett A, Sans S, Salomaa V, Kuulasmaa K, Dobson A, for the WHO MONICA 
Project. The effect of temperature on systolic blood pressure. Blood Press 
Monit. 2007;12:195-203.
38. Salomaa V, Dobson A, Miettinen H, Rajakangas A-M, Kuulasmaa K, for the 
WHO  MONICA  Project.  Mild  myocardial  infarction  -  a  classification 
problem in epidemiologic studies. J Clin Epidemiol. 1997;50:3-13.
39. Hense HW, Koivisto A-M, Kuulasmaa K, Zaborskis A, Kupsc W, Tuomilehto J, 
for the WHO MONICA Project. Assessment of blood pressure measurement 
quality  in  the  baseline  surveys  of  the  WHO  MONICA  Project.  J  Hum 
Hypertens. 1995; 9:935-46.
40. Tolonen H, Dobson A, Kulathinal S, for the WHO MONICA Project. Assessing 
the quality of risk factor survey data: lessons from the WHO MONICA 
Project. Eur J Cardiovasc Prev Rehabil. 2006;13:104-14.
41. Waterhouse  J,  Muir  CS,  Correa  P,  Powell  I,  eds.  Cancer  incidence  in  five 
continents. Lyon, IARC, 1976. Vol 3, p.456.
42. Tunstall-Pedoe H. Is acute coronary heart disease different in different countries 
in  the  two  sexes:  lessons  from  the  MONICA  Project.  Cardiovasc  Risk 
Factors. 1996;6:254-61.
43. Evans A, Salomaa V, Kulathinal S, Asplund K, Cambien F, Ferrario M, Percia 
M,  Peltonen  L,  Shields  D,  Tunstall-Pedoe  H,  Kuulasmaa  K  ,  for  the 
MORGAM Project. MORGAM (an international pooling of cardiovascular 
cohorts). Int J Epidemiol 2005; 34: 21-7.
44. Tunstall-Pedoe H, Connaghan J, Woodward M, Tolonen H, Kuulasmaa K, for 
the  WHO  MONICA  Project.  Pattern  of  declining  blood  pressure  across 
replicate population surveys of the WHO MONICA project, mid-1980s to 
mid-1990s, and the role of medication. BMJ. 2006;332:629-35.WHOMONICAProject:WhatHaveWeLearned? 395
45. Asplund K, Bonita R, Kuulasmaa K, Rajakangas A-M, Feigin V, Schädlich H, 
et al., for the WHO MONICA Project. Multinational comparisons of stroke 
epidemiology  -  evaluation  of  case-ascertainment  in  the WHO  MONICA 
stroke study. Stroke. 1995;26:355-60.
46. Sarti C, Stegmayr B, Tolonen H, Mähönen M, Tuomilehto J, Asplund J, for the 
WHO MONICA Project. Are changes in mortality from stroke caused by 
changes  in  stroke  event  rates  or  case  fatality?  Results  from  the  WHO 
MONICA Project. Stroke. 2003;34:1833-41.
47. Yarnell J, McCrum E, Rumley A, Patterson C, Salomaa V, Lowe G, et al., on 
behalf  of  the  MONICA  Optional  Haemostasis  Study  Investigators. 
Association of European population levels of thrombotic and inflammatory 
factors  with  risk  of  coronary  heart  disease:  the  MONICA  Optional 
Haemostasis Study. Eur Heart J. 2005;26:332-42.
48. Nuttens MC, Romon M, Ruidavets JB, Arveiler D, Ducimetiere P, Lecerf JM, 
et al. Relationship between smoking and diet: the MONICA-France project. 
J Internal Med. 1992;231:349-56.
49. Danet S, Richard F, Montaye M, Beauchant S, Lemaire B, Graux C, et al. 
Unhealthy effects of atmospheric temperature and pressure on the occurrence 
of myocardial infarction and coronary deaths: A 10-year survey: the Lille-
World  Health  Organization  MONICA  Project  (Monitoring  Trends  and 
Determinants in Cardiovascular Disease). Circulation. 1999;100:e1-e7.
50. Nilsson  M,  Trehn  G,  Asplund  K.  Use  of  complementary  and  alternative 
medicine remedies in Sweden. A population-based longitudinal study within 
the northern Sweden MONICA Project. J Internal Med. 2001;250:225-33.
51. Isaksson RM, Jansson JH, Lundblad D, Näslund U, Zingmark K, Eliasson M. 
Better long-term survival in young and middle-aged women than in men after 
a first myocardial infarction between 1985 and 2006: an analysis of 8630 
patients  in  the  Northern  Sweden  MONICA  Study.  BMC  Cardiovasc 
Disorders. 2011;11:1.
52. Lundblad  D,  Holmgren  L,  Jansson  JH,  Näslund  U,  Eliasson  M.  Gender 
differences in trends of acute myocardial infarction events: the Northern 
Sweden MONICA Study 1985-2004. BMC Cardiovasc Diseases. 2008;8:17.
53. Briffa T, Hickling S, Knuiman M, Hobbs M, Hung J, Sanfilippo FM, et al. Long 
term survival after evidence based treatment of acute myocardial infarction 
and revascularization: follow-up of population based Perth MONICA cohort, 
1984-2005. BMJ. 2009;338:b36.
54. Sans S, Puigdefábregas A, Paluzie G, Monterde D, Balaguer-Vintró I. Increasing 
trends  of  acute  myocardial  infarction  in  Spain:  the  MONICA-Catalonia 
Study. Eur Heart J. 2005;26:505-15.
55. Kuch  B, Wende  R,  Barac  M,  von  Scheidt W,  Kling  B,  Greschik  C,  et  al. 
Prognosis  and  outcomes  of  elderly  (75-84  years)  patients  with  acute 
myocardial infarction 1-2 years after the event – AMI-elderly study of the 
MONICA/KORA  Myocardial  Infarction  Registry.  Int  J  Cardiology. 
2011;149:205-10.396 PublicHealthReviews,Vol.33,No2
56. Pigeyre M, Dauchet L, Simon C, Bongard V, Bingham A, Arveiler D, et al. 
Effects of occupational and educational changes on obesity trends in France: 
the  results  of  the  MONICA-France  survey  1986-2006.  Prev  Med. 
2011;52:305-9.
57. Eriksson M, Holmgren L, Janlert U, Jansson JH, Lundblad D, Stegmayr B, et 
al. Large improvements in major cardiovascular risk factors in the population 
of  northern  Sweden:  the  MONICA  study  1986-2009.  J  Internal  Med. 
2010;269:219-31.
58. Imhof A, Woodward M, Doering A, Helbecque N, Loewel H, Amouyel P, et al. 
Overall alcohol intake, beer, wine, and systemic markers of inflammation in 
western Europe: results from three MONICA samples (Augsburg, Glasgow, 
Lille). Eur Heart J. 2004;25:2092-100.
59. Hense HW, Schulte H, Löwel H, Assmann G, Keil U. Framingham risk function 
overestimates  risk  of  coronary  heart  disease  in  men  and  women  from 
Germany – results from the MONICA Augsburg and the PROCAM cohorts. 
Eur Heart J. 2003;24:937-45.
60. Beck JA, Meisinger C, Heier M, Kuch B, Hörmann A, Greschik C, et al. Effect 
of blood glucose concentrations on admission in non-diabetic versus diabetic 
patients  with  first  acute  myocardial  infarction  on  short-  and  long-term 
mortality  (from  the  MONICA/KORA  Augsburg  Myocardial  Infarction 
Registry). Am J Cardiol. 2009;104:1607-12.
61. McDonagh TA, Woodward M, Morrison CE, McMurray JJV, Tunstall-Pedoe H, 
Lowe GDO, et al. Helicobacter pylori infection and coronary heart disease in 
the North Glasgow MONICA population. Eur Heart J. 1997;18:1257-60.
62. Euro  Heart  Survey.  Available  from  URL:  http://www.escardio.org/
guidelinessurveys/ehs/Pages/welcome.aspx (Accessed 26 September, 2011).
63. Feasibility of a European Health Examination Survey. Available from URL: 
http://www.ktl.fi/fehes/index.html (Accessed 26 September, 2011).
64. Levy RI, Causes of the decrease in cardiovascular mortality. Am J Cardiol. 
1984;54:7C-13C. 